<!DOCTYPE HTML>
<html>
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    <meta name="viewport" content="width=device-width, minimum-scale=1.0, maximum-scale=1.0">
    <title>Patient Cases</title>
    <link href="css/style.css" rel="stylesheet" type="text/css">
    <link href="css/normalize.css" rel="stylesheet" type="text/css">
    <link rel="stylesheet" href="css/jquery-ui.css"><!-- smoothness theme -->
    <link rel="stylesheet" href="css/jqbar.css" />
    <!-- dependencies -->
    <script type="text/javascript" src="js/jquery.tools.min.js"></script>
    <script type="text/javascript" src="js/jquery-ui-1.10.3.custom.min.js"></script>
    <!-- libraries -->
    <script type="text/javascript" src="js/jquery.ui.touch-punch.min.js"></script>
    <script type="text/javascript" src="js/ftscroller.js"></script>
    <script type="text/javascript" src="js/jquery.touchSwipe.min.js"></script>
    <script type="text/javascript" src="js/jquery.easing.min.js"></script>
    <script src="js/jqbar.js" type="text/javascript"></script>
    <!-- custom -->
    <script type="text/javascript" src="js/rabbit.js"></script>
    <script>
////    $(function() {
//      $( "#sortable" ).sortable({ axis: "y" });
//      $( "#sortable" ).disableSelection();
 // });

</script>
</head>

<body>
    <div class='mainContainer'>
        <div class='splash'>
            <div class='patient1-button splash-button' patient='1'></div>
            <div class='patient2-button splash-button' patient='2'></div>
            <div class='patient3-button splash-button' patient='3'></div>
            <div class='patient4-button splash-button' patient='4'></div>
        </div>
        <div class='swipeHome'></div>
        <div class='continueBtn'></div>
        <div class="page-content"></div>
        <div id="timeline" class='scrollable'>
            <div class='timeHot s1p1Hotspot timeline1Hotspot' timelinePosition='0'></div>
            <div class='timeHot s1p2Hotspot timeline1Hotspot' timelinePosition='97'></div>
            <div class='timeHot s1p3Hotspot timeline1Hotspot' timelinePosition='378'></div>
            <div class='timeHot s2p1Hotspot timeline2Hotspot' timelinePosition='0'></div>
            <div class='timeHot s2p2Hotspot timeline2Hotspot' timelinePosition='250'></div>
            <div class='timeHot s2p3Hotspot timeline2Hotspot' timelinePosition='649'></div>
            <div class='timeHot s2p4Hotspot timeline2Hotspot' timelinePosition='929'></div>
            <div class='timeHot s3p1Hotspot timeline3Hotspot' timelinePosition='0'></div>
            <div class='timeHot s3p2Hotspot timeline3Hotspot' timelinePosition='150'></div>
            <div class='timeHot s3p3Hotspot timeline3Hotspot' timelinePosition='697'></div>
            <div class='timeHot s3p4Hotspot timeline3Hotspot' timelinePosition='835'></div>
            <div id="timeline-arrow"></div>
        </div>
        <div class='backgroundDIV'></div>
        <img src="img/section2BG.jpg" class='hidden'> <img src="img/section3BG.jpg" class='hidden'> <img src="img/section4BG.jpg" class='hidden'> <img src="img/s1p1.png" class='hidden'> <img src="img/s1p2.png" class='hidden'> <img src="img/s1p3.png" class='hidden'> <img src="img/s2p1.png" class='hidden'> <img src="img/s2p2.png" class='hidden'> <img src="img/s2p3.png" class='hidden'> <img src="img/s2p4.png" class='hidden'> <img src="img/s3p1.png" class='hidden'> <img src="img/s3p2.png" class='hidden'> <img src="img/s3p3.png" class='hidden'> <img src="img/s3p4.png" class='hidden'> 

        <!-- MODAL CODAL -->
        <div class='modalBG'></div>
        <div class='pageModal'></div>
        <div class='modalContainer'>
            <div id='modalCloseBtn'></div>
            <div class='s1p1'><span class="dkBlue">Initial diagnosis: </span><br>
                <span class="blue">Stage IIB tumor identified in a routine mammogram</span>
                <ul>
                    <li>Mass identified in a routine mammogram, and excision biopsy&nbsp;performed</li>
                    <li>Diagnosis:
                        <ul class="em">
                            <li>Tumor: 3-cm IDC, 6/19 LN-positive. Classified as T2N2M0, AJCC stage IIIA </li>
                            <li>Endocrine status: ER/PR-negative</li>
                            <li>HER2 status: negative</li>
                        </ul>
                    </li>
                </ul>
                <div class="footnote">AC=doxorubicin and cyclophosphamide; AD=axillary dissection; AJCC=American Joint Committee on Cancer; ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; IDC=invasive ductal carcinoma; LN=lymph node; mets=metastases; MRM=modified radical mastectomy; PD=progressive disease; PR=progesterone receptor; XRT=external radiation therapy.</div>
            </div>
            <div class='s1p2'><span class="blue">Undergoes surgery and adjuvant treatment</span>
                <ul>
                    <li> Left MRM and AD performed</li>
                    <li>Adjuvant therapy (AC-based chemotherapy) followed by XRT to the left chest wall </li>
                </ul>
                <div class="footnote haterOffset">AC=doxorubicin and cyclophosphamide; AD=axillary dissection; mets=metastases; MRM=modified radical mastectomy; PD=progressive disease; XRT=external  radiation therapy.</div>
            </div>
            <div class='s1p3'><span class="blue">Metastatic disease relapse</span>
                <ul>
                    <li>4 months after adjuvant therapy, the patient developed pain in her lower back and legs; multiple lesions in hip and femur were detected on a bone scan </li>
                    <li> CT of chest, abdomen, and pelvis revealed 1 lung lesion (1 cm) </li>
                    <li> MRI showed no epidural involvement; received XRT and bone-modifying agent </li>
                    <li>Otherwise the patient is asymptomatic and takes ibuprofen for back pain </li>
                </ul>
                <div class="footnote">AC=doxorubicin and cyclophosphamide; AD=axillary dissection; CT=computed tomography; mets=metastases; MRI=magnetic resonance imaging; MRM=modified radical mastectomy; PD=progressive disease; XRT=external radiation therapy.</div>
            </div>
            <div class='s2p1'><span class="dkBlue">Initial diagnosis:</span><br>
                <span class="blue">Stage IIB tumor detected in self-examination</span>
                <ul>
                    <li>The patient detected a grape-size, movable, nontender mass in her right breast that gradually enlarged over a 3-month period </li>
                    <li>Patient went to the doctor after tenderness developed in her breast</li>
                    <li>Mammography confirmed the presence  of a suspicious lesion, and excision biopsy was performed </li>
                    <li>Diagnosis:
                        <ul class="em">
                            <li>Tumor: 5.5-cm IDC, N0. Classified as 		      T2N0M0, AJCC stage IIB </li>
                            <li>Endocrine status: ER/PR-negative </li>
                            <li>HER2 status: negative</li>
                        </ul>
                    </li>
                </ul>
                <div class="footnote" style="margin-top:0;">AJCC=American Joint Committee on Cancer; ER=estrogen receptor; HER2=human epidermal  growth factor receptor 2; IDC=invasive ductal carcinoma; mets=metastases; PD=progressive disease;  PR=progesterone receptor; XRT=external radiation therapy.</div>
            </div>
            <div class='s2p2'><span class="blue">Declines standard treatment for locally advanced disease</span><br>
                <ul>
                    <li>Originally diagnosed 2 years ago with resectable disease</li>
                    <li>The patient refused standard treatment and sought alternative therapy </li>
                </ul>
                <div class="footnote haterOffset">mets=metastases; PD=progressive disease; XRT=external radiation therapy.</div>
            </div>
            <div class='s2p3'><span class="blue">Untreated disease and metastatic progression</span><br>
                <ul>
                    <li>Admitted to emergency room 10 months ago with back pain and inability to walk </li>
                    <li>Patient assessed as ECOG PS 2 </li>
                    <li>CT scan of chest/abdomen and bone scans found liver and bone metastases </li>
                    <li>Regained ability to walk after acute steroid therapy and XRT to the lumbar spine </li>
                </ul>
                <div class="footnote haterOffset">CT=computed tomography; ECOG PS=Eastern Cooperative Oncology Group performance status; mets=metastases; PD=progressive disease; XRT=external radiation therapy. </div>
            </div>
            <div class='s2p4'><span class="blue">Combination chemotherapy to address residual&nbsp;metastases</span><br>
                <ul>
                    <li>History of cardiomyopathy with pregnancy; echocardiogram revealed decreased ejection fraction </li>
                    <li>Platinum-based therapy in first line was well tolerated </li>
                    <li>Patient achieved a partial response </li>
                    <li>Disease progressed after 7 months of treatment</li>
                </ul>
            </div>
            <div class='s3p1'><span class="dkBlue">Initial diagnosis:</span><br>
                <span class="blue">Stage IIIA tumor identified in a routine mammogram</span><br>
                <ul>
                    <li>Mass detected on routine annual mammogram recommended by her gynecologist </li>
                    <li>Received MRM with AD followed by XRT </li>
                    <li>Diagnosis:
                        <ul class="em">
                            <li>Tumor: 3-cm IDC, classified as T2N2M0, AJCC stage IIIA,                 5/10 LN-positive </li>
                            <li>Endocrine status: ER-positive/PR-negative </li>
                            <li>HER2 status: negative</li>
                        </ul>
                    </li>
                </ul>
                <div class="footnote">AC &#8594; T=doxorubicin, cyclophosphamide, and paclitaxel or docetaxel; AD=axillary dissection; AJCC=American Joint Committee on Cancer; ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; IDC=invasive ductal carcinoma; LN=lymph node; mets=metastases; MRM=modified radical mastectomy; PD=progressive disease; PR=progesterone receptor; XRT=external radiation therapy. </div>
            </div>
            <div class="s3p2"> <span class="blue"> Anthracycline-based adjuvant treatment</span><br>
                <ul>
                    <li>Adjuvant AC &#8594; T followed by tamoxifen </li>
                    <li>Therapy was well tolerated; patient became amenorrheic during chemotherapy</li>
                </ul>
                <div class="footnote haterOffset"> AC  &#8594; T=doxorubicin, cyclophosphamide, and paclitaxel or docetaxel; mets=metastases; MRM=modified radical mastectomy;  PD=progressive disease; XRT=external radiation therapy.</div>
            </div>
            <div class='s3p3'><span class="blue">Metastatic relapse after long-term hormonal therapy</span>
                <ul>
                    <li>After 3 years of tamoxifen therapy, patient complained of pain; bone scan revealed metastases </li>
                    <ul class="em">
                        <li>Biopsy of bone metastasis confirmed ER-positive,                 HER2-negative disease</li>
                    </ul>
                    <li>Patient remained amenorrheic; estradiol levels confirmed  she is postmenopausal </li>
                </ul>
                <div class="footnote">AC &#8594; T=doxorubicin, cyclophosphamide, and paclitaxel or docetaxel; ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; mets=metastases; MRM=modified  radical mastectomy; PD=progressive disease; PR=progesterone receptor; XRT=external radiation therapy.</div>
            </div>
            <div class='s3p4'><span class="blue">Repeated progression</span><br>
                <ul>
                    <li> Given anastrozole, bone-modifying agent, and XRT for bone metastases; pain subsided initially, but progression was seen after 6 months </li>
                    <li>The patient was treated with exemestane + everolimus </li>
                    <li>Further progression of bone metastases occurred at 5 months; CT scan revealed new liver metastases </li>
                    <li>Given capecitabine + ixabepilone; progressed again after 5.5 months</li>
                </ul>
                <div class="footnote">AC &#8594; T=doxorubicin, cyclophosphamide, and paclitaxel or docetaxel; CT=computed tomography; mets=metastases; MRM=modified radical mastectomy; PD=progressive disease; XRT=external radiation therapy. </div>
            </div>
        </div>
        <!-- MODAL CODAL --> 

        <!-- ISI PAGE START -->
        <div class='isiContainer'>
            <div class="closeBtn"></div>
            <div class="piBtn"></div>
            <div id="ISI">
                <div class='isiInner'> <strong>ABRAXANE<sup>&reg;</sup> for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
                    <div class="header">Important Safety Information</div>
                </strong>
                <div class="blackBox">
                    <div class='warning'><strong>WARNING - NEUTROPENIA</strong></div>
                    <ul style='margin-top:20px;'>
                        <li><strong>Do not administer ABRAXANE therapy to patients who have baseline neutrophil counts of less than 1,500 cells/mm&sup3;. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE </strong></li>
                        <li><strong>Note: An albumin form of paclitaxel may substantially affect a drug's functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS</strong></li>
                    </ul>
                </div>
                <div class='subheader'><strong>CONTRAINDICATIONS</strong></div>
                <strong>Neutrophil Counts</strong>
                <ul>
                    <li> ABRAXANE should not be used in patients who have baseline neutrophil counts of &lt; 1,500 cells/mm&sup3; </li>
                </ul>
                <strong>Hypersensitivity</strong>
                <ul>
                    <li>Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be rechallenged with the drug</li>
                </ul>
                <div class='subheader'><strong>WARNINGS AND PRECAUTIONS</strong></div>
                <strong>Hematologic Effects</strong>
                <ul>
                    <li> Bone marrow suppression (primarily neutropenia) is dose-dependent and a dose-limiting toxicity of ABRAXANE. In a clinical study, Grade 3-4 neutropenia occurred in 34% of patients with metastatic breast cancer (MBC) </li>
                    <li>Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Day 1 for MBC </li>
                    <li>Do not administer ABRAXANE to patients with baseline absolute neutrophil counts (ANC) of less than 1,500 cells/mm&sup3; </li>
                    <li>In the case of severe neutropenia (&lt;500 cells/mm&sup3; for 7 days or more) during a course of ABRAXANE therapy, reduce the dose of ABRAXANE in subsequent courses in patients with MBC </li>
                    <li>In patients with MBC, resume treatment with every-3-week cycles of ABRAXANE after ANC recovers to a level &gt;1,500 cells/mm&sup3; and platelets recover to &gt;100,000 cells/mm&sup3;</li>
                </ul>
                <strong>Nervous System</strong>
                <ul>
                    <li> Sensory neuropathy is dose- and schedule-dependent </li>
                    <li>The occurrence of Grade 1 or 2 sensory neuropathy does not generally require dose modification </li>
                    <li>If &ge; Grade 3 sensory neuropathy develops, treatment should be withheld until resolution to Grade 1 or 2 for MBC followed by a dose reduction for all subsequent courses of ABRAXANE</li>
                </ul>
                <strong>Hypersensitivity</strong>
                <ul>
                    <li> Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reported </li>
                    <li>Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be re-challenged with this drug</li>
                </ul>
                <strong>Hepatic Impairment</strong>
                <ul>
                    <li> Because the exposure and toxicity of paclitaxel can be increased with hepatic impairment, administration of ABRAXANE in patients with hepatic impairment should be performed with caution </li>
                    <li>The starting dose should be reduced for patients with moderate or severe hepatic impairment</li>
                </ul>
                <strong>Albumin (Human)</strong>
                <ul>
                    <li> ABRAXANE contains albumin (human), a derivative of human blood</li>
                </ul>
                <strong>Use in Pregnancy: Pregnancy Category D</strong>
                <ul>
                    <li>ABRAXANE can cause fetal harm when administered to a pregnant woman </li>
                    <li>If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus </li>
                    <li>Women of childbearing potential should be advised to avoid becoming pregnant while receiving ABRAXANE</li>
                </ul>
                <strong>Use in Men</strong>
                <ul>
                    <li> Men should be advised not to father a child while receiving ABRAXANE </li>
                </ul>
                <div class="subheader"><strong>ADVERSE REACTIONS</strong></div>
                <strong style="text-decoration:underline;">Randomized Metastatic Breast Cancer (MBC) Study</strong>
                <ul>
                    <li> The most common adverse reactions (&ge;20%) with single-agent use of ABRAXANE vs. Paclitaxel injection in the MBC study were alopecia (90%, 94%), neutropenia (all cases 80%,82%; severe 9%,22%), sensory neuropathy (any symptoms 71%, 56%; severe 10%, 2%), abnormal ECG (all patients 60%, 52%; patients with normal baseline 35%, 30%), fatigue/asthenia (any 47%, 39%; severe 8%, 3%), myalgia/arthralgia (any 44%, 49%; severe 8%, 4%), AST elevation (any 39%, 32%), alkaline phosphatase elevation (any 36%, 31%), anemia (all cases 33%, 25%; severe 1%, &lt;1%), nausea (any 30%, 22%; severe 3%, &lt;1%), diarrhea (any 27%, 15%; severe &lt;1%, 1%) and infections (24%, 20%), respectively </li>
                    <li>Sensory neuropathy was the cause of ABRAXANE discontinuation in 7/229 (3%) patients </li>
                    <li>Other adverse reactions of note with the use of ABRAXANE vs. Paclitaxel injection included vomiting (any 18%,10%; severe 4%, 1%), fluid retention (any 10%,8%; severe 0%,&lt;1%); mucositis (any 7%, 6%; severe &lt;1%, 0%), hepatic dysfunction (elevations in bilirubin 7%, 7%), hypersensitivity reactions (any 4%,12%; severe 0%, 2%), thrombocytopenia (any 2%, 3%; severe &lt;1%, &lt;1%), neutropenic sepsis (&lt;1%, &lt;1%), and injection site reactions (&lt;1%, 1%), respectively. Dehydration and pyrexia were also reported </li>
                    <li>Renal dysfunction (any 11%, severe 1%) were reported in patients treated with ABRAXANE (n = 229) </li>
                    <li>In all ABRAXANE treated patients (n=366) ocular/visual disturbances were reported (any 13%; severe 1%) </li>
                    <li>Severe cardiovascular events possibly related to single-agent ABRAXANE occurred in approximately 3% of patients and included cardiac ischemia/infarction, chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension </li>
                    <li>Cases of cerebrovascular attacks (strokes) and transient ischemic attacks have been reported </li>
                </ul>
                <strong>Post-marketing Experience With ABRAXANE and Other Paclitaxel Formulations</strong>
                <ul>
                    <li>Severe and sometimes fatal hypersensitivity reactions have been reported with ABRAXANE. The use of ABRAXANE in patients previously exhibiting hypersensitivity to paclitaxel injection or to human albumin has not been studied </li>
                    <li>There have been reports of congestive heart failure and left ventricular dysfunction with ABRAXANE, primarily among individuals with underlying cardiac history or prior exposure to cardiotoxic drugs </li>
                    <li>There have been reports of extravasation of ABRAXANE. Given the possibility of extravasation, it is advisable to monitor closely the ABRAXANE infusion site for possible infiltration during drug administration</li>
                </ul>
                <div class="subheader"><strong>DRUG INTERACTIONS</strong></div>
                <ul>
                    <li> Caution should be exercised when administering ABRAXANE concomitantly with medicines known to inhibit or induce either CYP2C8 or CYP3A4 </li>
                </ul>
                <div class="subheader"><strong>USE IN SPECIFIC POPULATIONS</strong></div>
                <strong>Nursing Mothers</strong>
                <ul>
                    <li> It is not known whether paclitaxel is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother</li>
                </ul>
                <strong>Pediatric</strong>
                <ul>
                    <li> The safety and effectiveness of ABRAXANE in pediatric patients have not been evaluated </li>
                </ul>
                <strong>Geriatric</strong>
                <ul>
                    <li> No toxicities occurred notably more frequently among patients &ge;65 years of age who received ABRAXANE for MBC </li>
                </ul>
                <strong>Renal Impairment</strong>
                <ul>
                    <li> The use of ABRAXANE has not been studied in patients with renal impairment</li>
                </ul>
                <div class="subheader"><strong>DOSAGE AND ADMINISTRATION</strong></div>
                <ul>
                    <li> Dose adjustment is recommended for patients with moderate and severe hepatic impairment and patients who experience severe neutropenia or severe sensory neuropathy during treatment with ABRAXANE </li>
                    <li> Withhold ABRAXANE if AST &gt;10 x ULN or bilirubin &gt;5 x ULN</li>
                    <li> Dose reductions or discontinuation may be needed based on severe hematologic or neurologic toxicities</li>
                    <li> Monitor patients closely </li>
                </ul>
                <strong>Please see full Prescribing Information, including Boxed WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.</strong> </div>
            </div>
        </div>
        <!-- ISI PAGE END --> 

        <!-- PI PAGE START -->
        <div class='piContainer'>

            <div class="closeBtn"></div>
            <div id="PI"> 
            	<img src="img/pdf/Abraxane_PrescribingInformation_Page_01.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_02.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_03.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_04.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_05.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_06.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_07.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_08.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_09.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_10.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_11.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_12.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_13.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_14.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_15.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_16.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_17.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_18.png"><br>
                <img src="img/pdf/Abraxane_PrescribingInformation_Page_19.png"><br>
            </div>
        </div>
        <!-- PI PAGE END --> 

        <!-- RISK ASSESSMENT -->
        <div class='raContainer'>

            <div class="closeBtn"> </div>
            <div class="piBtn"></div>
            <div id="RA">
                <section id="disease_chart">
                    <div id="radio">
                        <article class="question">Which disease factors are indicative of aggressive disease?</article>
                        <section class="row1">

                            <section class="factors"><span class='radioLabel' rel="div.info_modal:eq(0)" >Visceral metastases</span> </section>
                            <section class="choices">

                                <input type="radio" id="radio1" name="visceral"><label for="radio1">No</label>
                                <input type="radio" id="radio2" name="visceral"><label for="radio2">Yes</label>

                            </section>
                            <section class="patients"  rel="div.overlay:eq(0)"> </section>
                        </section>



                        <section class="row2">

                            <section class="factors"><span class='radioLabel' rel="div.info_modal:eq(1)" style='padding-top:5px;'>Number of<br>metastatic sites</span> </section>
                            <section class="choices">

                                <input type="radio" id="radio3" name="sites"><label for="radio3">&lt; 3</label>
                                <input type="radio" id="radio4" name="sites"><label for="radio4">&ge; 3</label>

                            </section>
                            <section class="patients"  rel="div.overlay:eq(1)"> </section>
                        </section>


                        <section class="row3">

                            <section class="factors"><span class='radioLabel' rel="div.info_modal:eq(2)">Disease-free interval</span> </section>
                            <section class="choices">


                                <input type="radio" id="radio9" name="Disease-free"><label for="radio9">&gt; 24 months</label>
                                <input type="radio" id="radio10" name="Disease-free"><label for="radio10">&le; 24 months</label>


                            </section>
                            <section class="patients"  rel="div.overlay:eq(1)"> </section>
                        </section>



                        <section class="row4">

                            <section class="factors"><span class='radioLabel' rel="div.info_modal:eq(3)" style='padding-top:5px;'>Response to<br>prior therapy</span> </section>
                            <section class="choices">


                                <input type="radio" id="radio7" name="Response"><label for="radio7">Yes</label>
                                <input type="radio" id="radio8" name="Response"><label for="radio8">No</label>


                            </section>
                            <section class="patients"  rel="div.overlay:eq(3)"> </section>
                        </section>


                        <section class="row5">

                            <section class="factors"><span class='radioLabel' rel="div.info_modal:eq(4)">Receptor status</span> </section>
                            <section class="choices">

                                <input type="radio" id="radio11" name="Receptor"><label for="radio11">HER2/HR</label>
                                <input type="radio" id="radio12" name="Receptor"><label for="radio12">Triple-negative</label>

                            </section>
                            <section class="patients" rel="div.overlay:eq(5)"> </section>

                        </section>
                        <!--- row6 -->


                        <section class="row6">


                            <section class="factors"><span class='radioLabel' rel="div.info_modal:eq(5)" >Symptomatic</span> </section>
                            <section class="choices">

                                <input type="radio" id="radio5" name="Symptomatic"><label for="radio5">No</label>
                                <input type="radio" id="radio6" name="Symptomatic"><label for="radio6">Yes</label>

                            </section>
                            <section class="patients"  rel="div.overlay:eq(2)"> </section>
                        </section>

                    </div> <!-- radio -->

                </section>  

                
                
            </div>
            
            
            <!--- END CONTENT -->
        <!---- pop-up content --->
        
        
        <!---- overlays ---->
        <!-- PLEASE NOTE THAT THE CLOSE BUTTON IN THE OVERLAYS CALLS A FUNC THAT RESETS THE CHART BAR BY DESTROYING ALL THE HTML IN THE BAR CONTAINER -->
        <div class="overlay" id="p1"> 
            <div class="close overlayClose"></div>
            <div class="modal case-button" id="top" patient="1"></div>
            <div class="modal case-button" id="middle" patient="2"></div>
            <div class="modal case-button" id="bottom" patient="3"></div>
            <div class=""></div>
            <div class=""></div>
        </div>
        
        <div class="overlay" id="p2">
            <div class="modal case-button" id="top" patient="1"></div>
            <div class="close overlayClose"></div>
            
        </div>
        
        <div class="overlay" id="p3">
            <div class="modal case-button" id="top" patient="2"></div>
            <div class="close overlayClose"></div>
            
        </div>
        
        <div class="overlay" id="p4">
            <div class="modal case-button" id="top" patient="3"></div>
            <div class="close overlayClose"></div>
            
        </div>
        
        <div class="overlay" id="p5">
        	<div class="close overlayClose"></div>
            <div class="modal case-button" id="top" patient="1"></div>
            
            
        </div>
        
        <div class="overlay" id="p6">
        	<div class="close overlayClose"></div>
            <div class="modal case-button" id="top" patient="1"></div>
            <div class="modal case-button" id="middle" patient="2"></div>
            
        </div>
        
        <!-- overlay -->
        <!--- INFO MODALS -->
        <!-- info 1 -->
        <div id="pop1" class='info_modal'>
            <div class="close popClose"><img src="img/closeBtn.png" alt="" height='60' width='60'></div>
            <div class="right_col">
                <div class="chartText1 bold">Visceral metastases are associated with more aggressive<br>metastatic breast cancer <span class='superscript'>7,a</span></div>
                <img class='chart1' src="img/pop_chart1_BG.png" alt="" height="268" width='438'>
                <div class='barContainer'>
                    <div id="bar1a"></div>
                    <div id="bar1b"></div>
                </div>
                <div class="foot1 footnote"><span class='superscript'>a</span> Univariate survival analysis from a retrospective database analysis of 346 patients with metastatic breast cancer after first recurrence. All patients had undergone surgery for primary breast cancer and may have received radiation, hormonal therapy, and/or chemotherapy for metastatic disease.
                </div>

            </div>
            <div class="left_col">
                <div class="copy">
                    <h1>Visceral metastases</h1>
                    <div>
                        <p>
                            A retrospective database analysis found that about 67%-73% of patients with metastatic breast cancer develop visceral metastases.<span class='superscript'>1</span> For approximately 57%-74% of patients, visceral metastases develop as the dominant site of metastases.<span class='superscript'>2,3</span> Further studies demonstrate that up to 85% of patients will develop visceral metastases at some time in the course of their disease.<span class='superscript'>1-6</span>
                        </p>
                        <p>
                            Visceral metastases are associated with more aggressive metastatic breast cancer compared with nonvisceral metastases; patients tend to have  worse outcomes.<span class='superscript'>2,3,7</span>
                        </p>
                    </div>
                    <div class="footnote">
                        <ol>
                            <li><span>1.</span> Samiee S et al. <em>Curr Oncol</em>. 2012;19:e270-e279.</li>
                            <li><span>2.</span> Gennari A et al. <em>Cancer</em>. 2005;104:1742-1750.</li>
                            <li><span>3.</span> Sledge GW et al. <em>J Clin Oncol</em>. 2003;21:588-592.</li>
                            <li><span>4.</span> Wallwiener M et al. <em>Breast Cancer Res Treat</em>. 2013;137:503-510.</li>
                            <li><span>5.</span> Loibl S et al. <em>Breast Care (Basel)</em>. 2011;6:457-461.</li>
                            <li><span>6.</span> Villanueva C et al. <em>Breast</em>. 2011;20:329-333.</li>
                            <li><span>7.</span> Chang J et al. <em>Cancer</em>. 2003;97:545-553. 
                            </li>
                        </ol>
                    </div>
                </div>
            </div>
            <footer>
                <div class='patient1-footer modal case-button close' patient='1'>
                    <img src="img/patient1-footer-thumb.png" alt="">
                    <div><img src="img/footer-text1.png" height='30' width='150' alt=""></div>
                </div>
                <div class='patient2-footer modal case-button close' patient='2'>
                    <img src="img/patient2-footer-thumb.png" alt="">
                    <div><img src="img/footer-text2.png" height='42' width='193' alt=""></div>
                </div>
                <div class='patient3-footer modal case-button close' patient='3'>
                    <img src="img/patient3-footer-thumb.png" alt="">
                    <div><img src="img/footer-text3.png" height='29' width='187' alt=""></div>
                </div>
            </footer>
        </div>
        
        <!-- second info modal -->
        <div id="pop2" class='info_modal'>
            <div class='close popClose'><img src="img/closeBtn.png" alt="" height='60' width='60'></div>
            <div class="right_col">
                <div class="chartText1 bold">Multiple metastatic sites are associated with a poor prognosis<span class='superscript'>2,a</span></div>
                <img class='chart2' src="img/pop_chart2_BG.png" width='458' height="261" alt="">
                <div class='barContainer'>
                    <div id="bar2a"></div>
                    <div id="bar2b"></div>
                    <div id="bar2c"></div>
                </div>
                <div class="foot2 footnote"><span class='superscript'>a</span> Univariate survival analysis of 1430 patients from 8 consecutive prospective trials conducted between 1977<br> and 1992 of anthracycline-based first-line chemotherapy in metastatic breast cancer. </div>

            </div>
            <div class="left_col">
                <div class="copy">
                    <h1>Number of<br>metastatic sites</h1>
                    <div>
                        <p>
                            The presence of multiple metastatic lesions or sites is associated with poor prognosis in patients with metastatic breast cancer.<span class='superscript'>1-3</span>
                        </p>
                    </div>
                    <div class="footnote">
                        <ol>
                            <li><span>1.</span> Jung SY et al. <em>Cancer Causes Control</em>. 2012;23:103-112.</li>
                            <li><span>2.</span> Pierga JY et al. <em>Ann Oncol</em>. 2001;12:231-237.</li>
                            <li><span>3.</span> Sledge GW et al. <em>J Clin Oncol</em>. 2003;21:588-592.</li>
                        </ol>
                    </div>
                </div>
            </div>
            <footer>
                <div class='patient1-footer modal case-button close' patient='1'>
                    <img src="img/patient1-footer-thumb.png" alt="" patient='1'>
                    <div><img src="img/footer-text1.png" height='30' width='150' alt=""></div>
                </div>
            </footer>
        </div>
        
        <!-- third info modal -->
        
        <div id="pop3" class='info_modal'>
            <div class='close popClose'><img src="img/closeBtn.png" alt="" height='60' width='60'></div>
            <div class="right_col">
                <div class="chartText3 bold">Short disease-free interval is associated with a poor prognosis<span class='superscript'>1,a,b</span>
                </div>
                <img class='chart3' src="img/pop_chart3.png" height='254' width='492'>
                <div class="foot3 footnote">  
                    <div style='text-indent:1px;'>Reproduced with permission from [Chang et al. <em>Cancer</em>. 2003;97:545-553].
                    </div>
                    <div style='text-indent:-5px;'><span class='superscript'>a</span> Multivariate survival analysis from a retrospective database of 346 patients with metastatic breast cancer after first&nbsp;recurrence.</div>
                    <div style='text-indent:-5px;'><span class='superscript'>b</span> Patients with lymph node–positive breast carcinoma who had developed distant, recurrent disease and had undergone radical/modified radical mastectomy or lumpectomy and axillary lymph node dissection with postoperative radiation therapy. Patients may have received radiation, hormonal therapy, and/or chemotherapy for metastatic disease.</div>
                </div>
                <div class="chartText3b bold">
                    <p>
                        A longer disease-free interval is associated with a better outcome<span class='superscript'>1,c</span>
                    </p>
                    <img src='img/pop_chart3b.png' height='102' width='332'>
                    <div class='footnote'>CI=confidence interval.
                        <p style='text-indent:-5px;'><span class='superscript'>c</span> Univariate survival analysis from a retrospective database of 346 patients with metastatic breast cancer after first recurrence. All patients had undergone surgery for primary breast cancer and may have received radiation, hormonal therapy, and/or chemotherapy for metastatic disease.
                        </p>
                    </div>
                    

                </div>
            </div>
            <div class="left_col">
                <div class="copy">
                    <h1>Disease-free interval</h1>
                    <div>
                        <p>A short disease-free interval <span class="nobreak">(&le;12–24</span> months) is independently associated with a worse outcome in patients with metastatic breast cancer.<span class='superscript'>1–3</span></p>
                    </div>
                    <div class="footnote">
                        <ol>
                            <li><span>1.</span> Chang J et al. <em>Cancer</em>. 2003;97:545-553.</li>
                            <li><span>2.</span> Pierga JY et al. <em>Ann Oncol</em>. 2001;12:231-237.</li>
                            <li><span>3.</span> Sledge GW et al. <em>J Clin Oncol</em>. 2003;21:588-592.</li>
                        </ol>
                    </div>
                </div>
            </div>
            <footer>
                <div class='patient1-footer modal case-button close' patient='1'>
                    <img src="img/patient1-footer-thumb.png" alt="">
                    <div><img src="img/footer-text1.png" height='30' width='150' alt=""></div>
                </div>
            </footer>
        </div>
        
        <!-- FOURTH info modal -->
        <div id="pop4" class='info_modal'>
            <div class='close popClose'><img src="img/closeBtn.png" alt="" height='60' width='60'></div>
            <div class="right_col">
                <img src="img/pop_chart4.png" height='543' width='649'>
            </div>
            <div class="left_col">
                <div class="copy">
                    <h1>Response to<br>prior therapy</h1>
                    <div>
                        <p>Achieving a response to first-line chemotherapy for patients with metastatic breast cancer is predictive of a better long-term outcome.<span class='superscript'>1-3</span></p>
                        <p>For patients with metastatic breast cancer who received first-line chemotherapy,  a worse outcome is predicted:
                            <ul>
                                <li>&bull; By failing to achieve any tumor response (complete or partial response)<span class='superscript'>1</span></li>
                                <li>&bull; By achieving an early response <span class='nobreak'>(&le;4&nbsp;months)</span> but rapidly relapsing within 8 months<span class='superscript'>1</span></li>
                                <li>&bull; If disease progression is observed at  the first tumor evaluation<span class='superscript'>3</span></li>
                            </ul>
                        </p>
                    </div>
                    <div class="footnote">
                        <ol>
                            <li><span>1.</span> Chang J et al. <em>Cancer</em>. 2003;97:545-553.</li>
                            <li><span>2.</span> Pierga JY et al. <em>Ann Oncol</em>. 2001;12:231-237.</li>
                            <li><span>3.</span> Sledge GW et al. <em>J Clin Oncol</em>. 2003;21:588-592.</li>
                        </ol>
                    </div>
                </div>
            </div>
            <footer>
               <div class='patient3-footer modal case-button close' patient='3'>
                <img src="img/patient3-footer-thumb.png" alt="">
                <div><img src="img/footer-text3.png" width='187' height='29' alt=""></div>
            </div>
        </footer>
    </div>
    
    <!-- FIFTH info modal -->
    <div id="pop5" class='info_modal'>
        <div class='close popClose'><img src="img/closeBtn.png" alt="" height='60' width='60'></div>
        <div class="right_col">
            <img src="img/pop_chart5.png" height='543' width='649'>
        </div>
        <div class="left_col">
            <div class="copy">
                <h1>Receptor status:<br>Triple-negative breast<br>cancer subtype<span class='superscript'>*</span></h1>
                <div>
                    <p>Tumor receptor expression has been demonstrated to correlate with outcomes. Compared with other types of breast cancer, ie, ER-, PR-, or HER2-positive, triple-negative breast cancers have a more aggressive clinical course with an increased likelihood of distant recurrence and death. Patients with triple-negative breast cancer have a worse outcome compared with patients diagnosed with the other subtypes.<span class='superscript'>1</span>

                        <ul>
                            <li>&bull; Approximately 12%–17% of patients diagnosed with breast cancer are also diagnosed with triple-negative disease <span class='superscript'>2</span></li>
                            <li>&bull; Studies report that about 7%-27% of patients with metastatic breast cancer have triple-negative breast cancer <span class='superscript'>3-5</span></li>
                        </ul>
                    </p>
                </div>
                <div class="footnote">
                    <div>
                        ER=estrogen receptor; HER2=human epidermal growth factor receptor 2;
                        PR=progesterone receptor.<br>* Information on the number of patients in the CA012 study with triple-negative breast cancer is not available, as it was not collected.
                    </div>
                    <ol>
                        <li><span>1.</span> Dent R et al. <em>Clin Cancer Res</em>. 2007;13:4429-4434.</li>
                        <li><span>2.</span> Foulkes WD et al. <em>N Engl J Med</em>. 2010;363:1938-1948.</li>
                        <li><span>3.</span> Thientosapol ES et al. <em>Intern Med J</em>. 2013;43(8):883-888.</li>
                        <li><span>4.</span> Villanueva C et al. <em>Breast</em>. 2011;20:329-333.</li>
                        <li><span>5.</span> Loibl S et al. <em>Breast Care (Basel)</em>. 2011;6:457-461.</li>
                    </ol>
                </div>
            </div>
        </div>
        <footer>
            <div class='patient1-footer modal case-button close' patient='1'>
                <img src="img/patient1-footer-thumb.png" alt="">
                <div><img src="img/footer-text1.png" height='30' width='150' alt=""></div>
            </div>
            <div class='patient2-footer modal case-button close' patient='2'>
                <img src="img/patient2-footer-thumb.png" alt="">
                <div><img src="img/footer-text2.png" height='42' width='193' alt=""></div>
            </div>
        </footer>
    </div>

    <!-- SIXTH MODAL -->
    <div id="pop6" class='info_modal'>
        <div class='close popClose'><img src="img/closeBtn.png" alt="" height='60' width='60'></div>
        <div class="right_col">
            <img src="img/pop_chart6.png" height='543' width='649'>
        </div>
        <div class="left_col">
            <div class="copy">
                <h1>Symptomatic</h1>
                <div>
                    <p>Patients with metastatic breast cancer often experience symptoms due to their disease.</p>

                    <p>The severity of symptoms has been shown to affect performance status  (eg, ECOG or Karnofsky scores).<span class='superscript'>1</span></p>
                    <ul>
                        <li>&bull; In patients with metastatic breast cancer, a poor performance status score increases the risk of death<span class='superscript'>2-4</span></li>

                    </ul>

                </div>
                <div class="footnote">
                    <ol>
                        <li><span>1.</span> Oken M et al. <em>Am J Clin Oncol</em>. 1982;5:649-655. </li>
                        <li><span>2.</span> Niikura N et al. <em>Oncologist</em>. 2011;16:155-164.</li>
                        <li><span>3.</span> Pierga JY et al. <em>Ann Oncol</em>. 2001;12:231-237.</li>
                        <li><span>4.</span> Gennari A et al. <em>Cancer</em>. 2005;104:1742-1750.</li>
                    </ol>
                </div>
            </div>
        </div>
        <footer>
            <div class='patient2-footer modal case-button close' patient='2'>
                <img src="img/patient2-footer-thumb.png" alt="">
                <div><img src="img/footer-text2.png" height='42' width='193' alt=""></div>
            </div>
        </footer>
    </div>
    
    <!--- END Info Modals -->
</div>



<!-- RISK ASSESSMENT END --> 
</div>
<script type="text/javascript" src="js/retina.js"></script>

<script type="text/javascript">
$(function() {
			// positions for each overlay
			//right side 'patient' pop ups
            var positions = [
            [215, 329],
            [290, 329],
            [365, 329],
            [440, 329],
            [515, 329],
            [590, 329]
            
            ];
			//left side 'info' pop ups
            var info_positions = [
            [60, 15],
            [60, 15],
            [60, 15],
            [60, 15],
            [60, 15],
            [60, 15]
            ];
            
				// setup triggers as IMG tags for the 'patient' pop ups
				$("section[rel]").each(function(i) {

					$(this).overlay({

						// common configuration for each overlay
						// only one modal at any time
						// click off of modal to close
						// also will close by hitting escape by default
						oneInstance: true,
						closeOnClick: true,

						// setup custom finish position
						top: positions[i][0],
						left: positions[i][1],
						
						// mask layer that allows for clicking off to close
						// no color 
						mask: {
							maskId: "defaultMask" ,
							color: null ,
							zIndex: 9001
						},
						// pop out overlay from click point
						effect: "apple",
						zIndex: 9100
					});
				});
				// setup triggers of the 'info' pop ups
				$("section.factors span[rel]").each(function(i) {

					$(this).overlay({

						// common configuration for each overlay
						oneInstance: true,
						closeOnClick: true,

						// setup custom finish position
						top: info_positions[i][0],
						left: info_positions[i][1],
						
						// mask layer that allows for clicking off to close
						// no color
						mask: {
							maskId: "defaultMask" ,
							color: null ,
							zIndex: 9000
						},
                        onLoad: function(){
                            triggerRef = this.getTrigger();//IDENTIFY THE TRIGGERING OBJECT
                            startChart(triggerRef);//SEND THE OBJECT TO THE FUCNTION THAT WILL TRIGGER THE CHART ANIMATION
                        },
						// pop out overlay from click point
						effect: "apple",
						zIndex: 9100
					});
				});
			});
/** choices section - styling of radio button elements as boolean tabs **/
$( "#radio" ).buttonset();


			//prevent pulling iPad browser window with swipes
			document.body.addEventListener('touchmove', function(event) {
				event.preventDefault();
			}, false); 
            function startChart(aThing){// FUNCTION THAT STARTS THE CHART ANIMATION
                relString = $(aThing).attr('rel');//GRAB THE IDENTIFYING INFORMATION FROM THE REL ATTRIBUTE
                relString = relString.replace(/\D/g,'');//STRIP THE CHARACTERS COMMON TO ALL THE TRIGGER OBJECTS USING REGEX
                if (relString == 0) {
                 $('#bar1a').jqbar({ label: 'Nonvisceral', value: 23.2, barColor: '#97999d',barWidth: 54, barLength: 1600});
                 $('#bar1b').jqbar({ label: 'Visceral', value: 10.9, barColor: '#0c5fa7',barWidth: 54, barLength: 1600}); 
             } else if(relString == 1){
                $('#bar2a').jqbar({value: 19.3, barColor: '#0c5fa7',barWidth: 43, barLength: 1000});
                $('#bar2b').jqbar({value: 24.5, barColor: '#505354',barWidth: 43, barLength: 1000});
                $('#bar2c').jqbar({value: 31.3, barColor: '#97999d',barWidth: 43, barLength: 1000});
                
            };



            console.log(relString);
        }

        </script>
    </body>
    </html>